CADD522 shows promise against osteoporosis
Analysis based on 8 articles · First reported Sep 07, 2026 · Last updated Sep 08, 2026
The findings could stimulate interest in CADD522 as a potential osteoporosis treatment, potentially benefiting the developers and investors in the pharmaceutical sector. However, as the drug is in early preclinical stages, significant time and investment are needed before any market impact materializes.
Researchers at the University of East Anglia, collaborating with the University of Maryland, College Park, the International Rice Research Institute, and the University of Stirling, published a peer-reviewed experimental study in npj Drug Discovery showing that CADD522, a drug originally developed as a cancer treatment, improved bone health and reduced body fat in post-menopausal mice. The drug, a RUNX2 inhibitor, increased bone volume and preserved bone microarchitecture, while also reducing weight and fat deposits in bone marrow. Safety testing in mice, rats, and dogs showed the drug was orally bioavailable and well tolerated. The research is at an early animal-testing stage, and the team hopes the benefits will translate to humans.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard